In a bid to strengthen its branded portfolio, pharma major Lupin is looking for alliances and eyeing strategic brand acquisitions in US markets in 2015-16. The United States is Lupin’s largest market and contributed 45 per cent of the company’s revenues in 2014-15.
In 2015-16, the company remains committed to continuing to strengthen its branded portfolio with the launch of additional products by not only creating alliances but also developing its own pipeline and making strategic brand acquisitions in US markets.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.
